97 related articles for article (PubMed ID: 27009118)
1. Commentary: Adaptive PTEN Loss Enhances the Outgrowth of Brain Metastatic Tumour Cells.
Kumar VS; Krishnamurthy RG
CNS Neurol Disord Drug Targets; 2016; 15(3):262-4. PubMed ID: 27009118
[No Abstract] [Full Text] [Related]
2. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth.
Zhang L; Zhang S; Yao J; Lowery FJ; Zhang Q; Huang WC; Li P; Li M; Wang X; Zhang C; Wang H; Ellis K; Cheerathodi M; McCarty JH; Palmieri D; Saunus J; Lakhani S; Huang S; Sahin AA; Aldape KD; Steeg PS; Yu D
Nature; 2015 Nov; 527(7576):100-104. PubMed ID: 26479035
[TBL] [Abstract][Full Text] [Related]
3. Microenvironment: Astrocytes silence PTEN to promote brain metastasis.
Shipman L
Nat Rev Cancer; 2015 Dec; 15(12):695. PubMed ID: 26563461
[No Abstract] [Full Text] [Related]
4. Welcoming Treat: Astrocyte-Derived Exosomes Induce PTEN Suppression to Foster Brain Metastasis.
Alečković M; Kang Y
Cancer Cell; 2015 Nov; 28(5):554-556. PubMed ID: 26555172
[TBL] [Abstract][Full Text] [Related]
5. [When gliomes go hand in hand with exosomes].
Larsen CJ
Bull Cancer; 2016 Mar; 103(3):222-3. PubMed ID: 26902155
[No Abstract] [Full Text] [Related]
6. Brain May Prime Metastatic Cell Growth.
Cancer Discov; 2016 Jan; 6(1):OF2. PubMed ID: 26621760
[TBL] [Abstract][Full Text] [Related]
7. PTEN alterations of the stromal cells characterise an aggressive subpopulation of pancreatic cancer with enhanced metastatic potential.
Wartenberg M; Centeno I; Haemmig S; Vassella E; Zlobec I; Galván JA; Neuenschwander M; Schlup C; Gloor B; Lugli A; Perren A; Karamitopoulou E
Eur J Cancer; 2016 Sep; 65():80-90. PubMed ID: 27475963
[TBL] [Abstract][Full Text] [Related]
8. Microenvironment: Tumour-promoting tissue mechanics.
Lokody I
Nat Rev Cancer; 2014 May; 14(5):296. PubMed ID: 24705651
[No Abstract] [Full Text] [Related]
9. High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model.
Wei Q; Clarke L; Scheidenhelm DK; Qian B; Tong A; Sabha N; Karim Z; Bock NA; Reti R; Swoboda R; Purev E; Lavoie JF; Bajenaru ML; Shannon P; Herlyn D; Kaplan D; Henkelman RM; Gutmann DH; Guha A
Cancer Res; 2006 Aug; 66(15):7429-37. PubMed ID: 16885338
[TBL] [Abstract][Full Text] [Related]
10. PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma.
Boelens MC; Nethe M; Klarenbeek S; de Ruiter JR; Schut E; Bonzanni N; Zeeman AL; Wientjens E; van der Burg E; Wessels L; van Amerongen R; Jonkers J
Cell Rep; 2016 Aug; 16(8):2087-2101. PubMed ID: 27524621
[TBL] [Abstract][Full Text] [Related]
11. Exosomes in virus-associated cancer.
Wu J; Yang J; Ding J; Guo X; Zhu XQ; Zheng Y
Cancer Lett; 2018 Dec; 438():44-51. PubMed ID: 30219505
[TBL] [Abstract][Full Text] [Related]
12. Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma.
Liu T; Chen G; Sun D; Lei M; Li Y; Zhou C; Li X; Xue W; Wang H; Liu C; Xu J
Acta Biochim Biophys Sin (Shanghai); 2017 Sep; 49(9):808-816. PubMed ID: 28910982
[TBL] [Abstract][Full Text] [Related]
13. Exosome-derived microRNAs in cancer metabolism: possible implications in cancer diagnostics and therapy.
Tomasetti M; Lee W; Santarelli L; Neuzil J
Exp Mol Med; 2017 Jan; 49(1):e285. PubMed ID: 28104913
[TBL] [Abstract][Full Text] [Related]
14. Stromal miR-320 keeps an oncogenic secretome in check.
Khew-Goodall Y; Goodall GJ
Nat Cell Biol; 2012 Feb; 14(2):124-5. PubMed ID: 22298040
[No Abstract] [Full Text] [Related]
15. Cancer-associated fibroblasts release exosomal microRNAs that dictate an aggressive phenotype in breast cancer.
Donnarumma E; Fiore D; Nappa M; Roscigno G; Adamo A; Iaboni M; Russo V; Affinito A; Puoti I; Quintavalle C; Rienzo A; Piscuoglio S; Thomas R; Condorelli G
Oncotarget; 2017 Mar; 8(12):19592-19608. PubMed ID: 28121625
[TBL] [Abstract][Full Text] [Related]
16. Exosomes decrease sensitivity of breast cancer cells to adriamycin by delivering microRNAs.
Mao L; Li J; Chen WX; Cai YQ; Yu DD; Zhong SL; Zhao JH; Zhou JW; Tang JH
Tumour Biol; 2016 Apr; 37(4):5247-56. PubMed ID: 26555545
[TBL] [Abstract][Full Text] [Related]
17. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
[TBL] [Abstract][Full Text] [Related]
18. Tracking Down Response and Resistance to TRK Inhibitors.
Okimoto RA; Bivona TG
Cancer Discov; 2016 Jan; 6(1):14-6. PubMed ID: 26747892
[TBL] [Abstract][Full Text] [Related]
19. ECM stiffness paves the way for tumor cells.
Seewaldt V
Nat Med; 2014 Apr; 20(4):332-3. PubMed ID: 24710372
[No Abstract] [Full Text] [Related]
20. The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation.
Alfonsi R; Grassi L; Signore M; Bonci D
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29652798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
